12 Jan 2022 --- A clinical trial has found that a probiotic formulation from AB-Biotics, part of the Kaneka Group, exhibits “significant” positive effects in COVID-19 outpatients – possibly by influencing the gut-lung axis (GLA). Notably, AB21 was associated with reduced viral load, duration of symptoms and improved rate of remission.
.png)
